NeuroNova is a developer and provider of novel therapies for disorders of the central nervous system. They have developed drug candidates, such as sNN0029 for amyotrophic lateral sclerosis and sNN0031 for moderate to severe Parkinson's disease. These candidates are designed to act on neural stem and progenitor cells in the brain. Additionally, NeuroNova focuses on developing therapeutic products based on neurogenesis to address unmet medical needs in neurodegenerative diseases.